Cytokinetics Inc (CYTK) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.

Total Revenue Chart for Cytokinetics Inc

Cytokinetics Inc (CYTK) revenue for FY2025 was USD 88.0M, a 376.6% change from FY2024. Cytokinetics Inc's revenue grew from USD 8.5M in 2001 to USD 88.0M in 2025 (939.9% over 24 years). Earnings per share grew from USD 2.54 in 2009 to USD -4.33 in 2022 (-270.4%). Revenue compound annual growth rate: 5-year CAGR of 9.5%, 10-year CAGR of 11.9%, 20-year CAGR of 12.1%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$8.53B
Implied Share Price
$61.35
Enterprise Value
$9.26B
Revenue (TTM)
$67.67M
EBITDA
-$695.36M
Profit Margin
0.00%
Trailing P/E
—
Forward P/E
117.65
Price/Book (MRQ)
60.31
Price/Sales (TTM)
126.04
EV/EBITDA
-15.82
EV/Revenue
145.20
Dividend Yield
—
Book Value
$-1.25
Free Cash Flow (FY2025)
-$534.82M
Free Cash Flow Yield
-6.27%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.